Allarity Therapeutics is a clinical-stage precision medicine biopharmaceutical company dedicated to developing personalized cancer treatments for patients with difficult-to-treat malignancies. The company's lead program focuses on stenoparib, a novel orally available dual inhibitor of PARP1/2 and tankyrase 1/2, currently in Phase 2 clinical trials for advanced, platinum-resistant, and platinum-ineligible ovarian cancer. The company received FDA Fast Track designation for stenoparib in ovarian cancer, enabling expedited development and review pathways. A cornerstone of Allarity's strategy is its proprietary Drug Response Predictor (DRP®) companion diagnostic platform, which uses gene expression signatures to identify patients most likely to benefit from specific therapies, enabling a precision medicine approach to oncology. Beyond ovarian cancer, the company is expanding stenoparib's clinical potential into other advanced cancers, including a Phase 2 trial in recurrent small cell lung cancer funded by the U.S. Veterans Administration. Headquartered in the United States with research operations in Denmark, Allarity also generates revenue through licensing and laboratory services agreements that provide external partners access to DRP® diagnostic algorithms and transcriptomic testing services.